Holen Sie sich die Stockscreener-App
8.28
4.81%
0.38
Vorhandelsmarkt:
8.43
0.15
+1.81%
Schlusskurs vom Vortag:
$7.90
Offen:
$8.07
24-Stunden-Volumen:
100.43K
Relative Volume:
1.25
Marktkapitalisierung:
$797.64M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
88.56
EPS:
0.0935
Netto-Cashflow:
$6.37M
1W Leistung:
-4.28%
1M Leistung:
+6.56%
6M Leistung:
+9.23%
1J Leistung:
-24.04%
1-Tages-Spanne:
$8.02
$8.48
1-Wochen-Bereich:
$7.83
$8.98
52-Wochen-Spanne:
$6.11
$13.75
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(858) 567-7770
Adresse
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.28 | 761.03M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
GYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal - TipRanks
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2%Should You Buy? - MarketBeat
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock By Investing.com - Investing.com UK
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock - Investing.com Nigeria
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger - TipRanks
Gyre Therapeutics (NASDAQ: GYRE) inks $300M all-stock Cullgen deal - Stock Titan
Gyre Therapeutics enters into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline - marketscreener.com
Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline - TradingView
Gyre Therapeutics to acquire Cullgen for $300 million - Investing.com
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
getLinesFromResByArray error: size == 0 - mfd.ru
Gyre Therapeutics, Inc. entered into an agreement to acquire Cullgen Inc. - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 111% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Risks Report: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Big Picture: How do insiders feel about Gyre Therapeutics Inc2025 Valuation Update & Trade Opportunity Analysis - baoquankhu1.vn
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aug Selloffs: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Can Gyre Therapeutics Inc. scale operations efficientlyJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - mfd.ru
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Capitalizing on a Promising 113.78% Upside - DirectorsTalk Interviews
Market Catalysts: Can Gyre Therapeutics Inc weather a recessionTreasury Yields & Daily Entry Point Trade Alerts - baoquankhu1.vn
Can Gyre Therapeutics Inc. maintain its current growth ratePortfolio Update Report & Safe Entry Zone Tips - mfd.ru
GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty - TipRanks
High Growth Tech Stocks in US for February 2026 - simplywall.st
Will Gyre Therapeutics Inc outperform tech stocks2025 Price Action Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) Last Week's 8.5% Decline Must Have Disappointed Public Companies Who Have a Significant Stake - 富途牛牛
Returns Recap: Is TENPREs ROIC above industry averageWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a Promising 139.68% Upside Potential - DirectorsTalk Interviews
Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN
What dividend growth rate does Gyre Therapeutics Inc. offer2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - mfd.ru
Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX) - Defense World
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Eyeing a 119% Upside with a Strong Buy Consensus - DirectorsTalk Interviews
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.4%Still a Buy? - MarketBeat
Big Money Moves: Is MicroSectors Travel 3X Leveraged ETNs due May 29 2042 showing insider buyingWeekly Trading Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Aug Big Picture: Is Gyre Therapeutics Inc a turnaround storyJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Trade Recap: Can Palantir Technologies Inc navigate macro headwindsMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: A Potential 123% Upside in the Biotech Space - DirectorsTalk Interviews
US Stocks Recap: Can Gyre Therapeutics Inc expand into new marketsWeekly Trade Analysis & Community Driven Trade Alerts - baoquankhu1.vn
Portfolio Recap: Is BCGWW a good ESG investment2025 Market Overview & Community Verified Swing Trade Signals - baoquankhu1.vn
Quarterly Risk: Does Evolus Inc have high return on assetsJuly 2025 WrapUp & High Accuracy Swing Trade Signals - baoquankhu1.vn
Tech Rally: Is TRTNPRC stock a value trapWeekly Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Pulse: Will Gyre Therapeutics Inc outperform tech stocksJuly 2025 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
Ideas Watch: What are analysts price targets for Gyre Therapeutics IncIPO Watch & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):